Welcome to our dedicated page for MINIMED GROUP SEC filings (Ticker: MMED), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on MINIMED GROUP's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into MINIMED GROUP's regulatory disclosures and financial reporting.
MiniMed Group, Inc. director Endicott David J. filed an initial Form 3, which is a statement of beneficial ownership for company insiders. The filing shows no reported transactions and no listed holdings of MiniMed Group securities in the provided data.
MiniMed Group, Inc. director Linnea Burman has filed an initial Form 3 reporting status as an insider of the company. The filing shows no reported transactions or holdings, with zero shares listed for purchases, sales, exercises, gifts, tax withholding, or restructurings.
MiniMed Group, Inc. senior vice president and general counsel Courtney Nelson reported equity compensation grants of common stock on July 1, 2026. The Form 4 shows two awards totaling 22,057 and 60,730 shares, each recorded at $0.00 per share as compensation rather than open-market purchases.
Footnotes state these represent restricted stock units granted under the 2026 Long Term Incentive Plan. One grant vests in roughly equal one-third installments on the first, second and third anniversaries of the grant date, while the other vests on the third anniversary. Following these awards, the filing reports updated direct holdings of 138,146 and 116,089 common shares in the respective lines, including shares issuable upon RSU vesting and 296 shares acquired via the 2026 Employee Stock Purchase Plan.
MiniMed Group, Inc. executive Gyurci John, VP and Chief Accounting Officer, reported an equity compensation grant rather than a market purchase or sale. He received 24,244 shares of Common Stock as a grant of restricted stock units under the 2026 Long Term Incentive Plan, with these RSUs vesting in approximately equal one-third increments on the first, second and third anniversaries of the grant date. Following this award, his directly held position is reported as 39,941 shares of common stock, which includes shares issuable upon vesting of one or more RSUs and 375 shares acquired through MiniMed’s 2026 Employee Stock Purchase Plan.
MiniMed Group, Inc. senior vice president and chief HR officer Gillian Chandrasena reported two equity compensation grants of common stock on July 1, 2026. Both transactions are coded as awards, not open‑market purchases or sales.
The filing shows one grant of 14,705 restricted stock units (RSUs) under the 2026 Long Term Incentive Plan that vest in approximately equal one‑third increments on the first, second and third anniversaries of the grant date. A second RSU grant of 29,483 shares vests on the third anniversary of the grant date. Following these awards, reported direct holdings include common stock and shares that will be issued as RSUs vest, as well as 891 shares acquired under the 2026 Employee Stock Purchase Plan on June 30, 2026.
Spooner Chad reported acquisition or exercise transactions in this Form 4 filing.
MiniMed Group, Inc. reported that EVP and Chief Financial Officer Chad Spooner received equity-based compensation in the form of restricted stock units tied to common stock. He was granted 22,057 shares that vest in three equal annual installments and 94,550 shares that vest on the third anniversary of the grant date.
Both awards were granted at no cash cost per share and are part of the 2026 MiniMed Group, Inc. Long Term Incentive Plan. Following these grants, Spooner directly holds more than 360,000 shares of common stock, indicating this is a compensation-related increase rather than an open-market purchase.
MiniMed Group, Inc. reported that officer Ali Dianaty received two equity awards of common stock on July 1, 2026. The filing shows grants classified as restricted stock units under the 2026 Long Term Incentive Plan, covering 36,762 shares and 94,550 shares of common stock at no cash cost.
The RSUs tied to these awards vest over time, with one grant vesting in approximately equal one-third increments on the first, second and third anniversaries of the grant date, and another vesting on the third anniversary. Existing holdings also include shares to be issued upon vesting of prior RSUs and 600 shares acquired under the 2026 Employee Stock Purchase Plan.
MiniMed Group, Inc. reported that Chief Executive Officer Dallara Que received a grant of 297,618 restricted stock units (RSUs) of common stock at no cost, described as a grant, award or other acquisition under the company’s 2026 Long Term Incentive Plan.
The RSUs vest in approximately equal one-third increments on the first, second and third anniversaries of the grant date, tying most of the benefit to future service and performance. Following this award, Que holds 916,099 shares of common stock, including shares expected to be issued upon vesting of one or more RSUs and 1,727 shares acquired through the 2026 Employee Stock Purchase Plan.
MiniMed Group, Inc. filed an initial Form 3 for director Cundy Scott T. This filing establishes his status as a reporting person for MiniMed Group but does not list any current holdings or report any buy, sell, or other insider transactions.
MiniMed Group, Inc. outlines its diabetes-technology business and recent performance in this annual report. The company develops integrated insulin pumps, continuous glucose monitors, smart dosing algorithms, and software platforms such as CareLink to serve people with type 1 and insulin‑requiring type 2 diabetes worldwide.
Revenue reached $3.1 billion in fiscal 2026, up from $2.7 billion in 2025, but MiniMed reported net losses of $317 million and $198 million, respectively, alongside positive Adjusted EBITDA. The filing highlights strong real‑world clinical data for the MiniMed 780G automated insulin delivery system, significant international exposure, and a deep pipeline including the MiniMed Flex pump, MiniMed Fit patch pump, and the Vivera “hands‑free” dosing algorithm.